Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974875 | 0.89 | ESR2 (0.62) | MAPK1NR1H2ESR2DDB1CRBN | |
| SCHEMBL31233601 | 0.82 | CRBN (0.48) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL29676965 | 0.81 | MAPK1 (0.64) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL5183098 | 0.81 | MAPK1 (0.64) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL2344939 | 0.80 | NR1H2 (0.50) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL9182719 | 0.80 | ESR2 (0.49) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL2292608 | 0.78 | USP2 (0.52) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL30830966 | 0.77 | NR1H2 (0.52) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL26802733 | 0.77 | NR1H2 (0.52) | MAPK1NR1H2ESR2HDAC1DDB1 | |
| SCHEMBL29385334 | 0.77 | MEN1 (0.39) | MAPK1NR1H2ESR2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061261-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| CN-109311897-A | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | 福马治疗股份有限公司 | 2019-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | MAPK1 1832/4885NR1H2 4133/4885ESR2 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.